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Abstract: Even though hepatoblastoma is the most common malignant hepatic tumour in children, it is still a rarely 
encountered childhood tumour. Survival outcome is better with the favorable histologic subtype. This report is focused on 
raising increase awareness of this rare tumour in our environment and also to report the outcome of management of two 
cases based on already established collaborative multicentre clinical trial studies. 
The first case was a 6week old girl with a painless abdominal mass presenting in acute respiratory distress with severe 
anaemia. The serum level of AFP was ≥ 107,000ng/ml. Right tri segmentectomy was performed for excision of the 
pedunculated liver mass. Histology of the mass was consistent with hepatoblastoma with predominance of fetal 
components. Complete course of adjuvant cisplatin 3mg/kg mono therapy was administered. 
The second case was a 7 year old, healthy looking girl presenting with a slow growing abdominal mass for 6 years. Her 
serum AFP level was ≥ 10,000ng/ml. At surgery an encapsulated huge gray looking tumour was found on the right lobe 
of the liver. An extended right hepatectomy was performed to remove the tumour. Histology revealed hepatoblastoma 
with teratoid components. Complete course of adjuvant chemotherapy made up of cisplatin 60/mg2in combination with 
doxorubicin 30/mg2 was administered. 
Both patients did well and had uneventful follow-ups. 
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INTRODUCTION 
Unlike nephroblastoma, hepatoblastoma is an 
uncommon paediatric embryonic tumour in our 
environment, [1] probably because of low survival rate 
of children from those recognized risk factors in our 
setting. Overall, it represents 1% of all paediatric 
tumours, and is by far the most common malignant 
hepatic tumour that occurs only in children [2]. 
Mesenchymal hamartoma, infantile haemangioendo- 
thelioma, undifferentiated embryonal sarcoma and 
rhabdomyosarcoma of the biliary tract are also other 
rare hepatic tumours found only in children. 
Hepatoblastoma primarily arises from the pluripotent 
stem cells of the liver of the embryo. Majority 
developed before 3 years of age, and has a distinct 
male preponderance, in a ratio 2:1 male-to-female [3]. 
The much report about improved survival outcome 
from hepatoblastoma have been primarily due to 
improved diagnosis and treatment according to 
protocols developed from large multicentre 
collaborative clinical trial studies [4-7]. 
This report is aim at raising awareness for such an 
unfamiliar tumour in our environment, also report the 
outcome of management of two cases in our setting as 
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according to multicentre collaborative clinical trial 
studies. 
CASE 1 
A 6 week old girl the first set of twins delivered by a 
19 years old house wife to a family of non 
consanguineous parents after 39 weeks of 
unsupervised pregnancy. She presented with 
abdominal distention, respiratory distress, constipation 
and vomiting for 4 days. Examination revealed an 
acutely ill child, dyspnaeic (respiratory rate 68 
cycles/min) and dehydrated, pale (packed cell volume 
25%), anicteric, afebrile (temperature 37.10C), heart 
rate 168 beats/min. Her weight was 3.65 kg, 73% of the 
expected. She had a right hypochondrial mass 
extending toward the epigastrium, which was hard and 
irregular. The mass measures about 8cm below the 
right sub costal margin. Rectum and other system 
examinations were unremarkable. The mass was 
shown arising on the right lobe of the liver, hyperechoic 
and measures 10.2 x 8.0 x 9.7cm on abdominal 
ultrasound scan. Intrahepatic bile ductules were not 
dilated. Liver function test, full blood count, and 
absolute platelet, clotting profile, electrolytes, urea and 
creatinine and viral screening were normal. Serum 
alpha-feto protein (AFP) level was ≥ 107,000ng/ml. 
After stabilization, the peritoneum was opened through 
a transverse supra umbilical incision. Intraoperatively, 
an encapsulated and pedunculated, huge grayish 
looking mass was found on the anterio-lateral surface 
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of the liver (stage I) Children’s Oncology Group (COG) 
clinical staging system, [8] Figure 1. Right 
trisegmentectomy was performed using diathermy 
coagulation in combination with Pringles maneuver of 
the portal inflows to remove the mass. 150mls of fresh 
blood was transfused intra operatively. The peritoneum 
was closed over a sub hepatic drain, which was 
removed after three days. Histology revealed immature 
hepatocytic elements disposed in solid sheets, and 
nest devoid of mitotic cells with scanty neoplasm which 
were consistent with hepatoblastoma with predominant 
fetal component. Pre chemotherapy haematological 
parameters were unremarkable. She received 5 
courses of three weekly adjuvant cisplatin (CDDP) 
3mg/kg in 250mls of intravenous fluid slowly for 5 
hours. She was transfused on two separate occasions 
during the course of the chemotherapy. The post 
chemotherapy serum alpha-feto protein was ≤ 20ng/ml. 
Her follow up had been uneventful. 
CASE 2 
A 7 year old girl, with a slow growing right 
hypochondrial swelling for 6yearduration, sometimes 
associated with dull aching non radiating pain. No any 
other compliant. She had uneventful pregnancy and 
 
Figure 1a: Intra operative appearance of the liver mass in the 6 weeks old girl. 
 
Figure 1b: Postoperative appearance of the mass after it was excised in a 6 weeks old girl. 
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delivery. The mother was 18 years old at the time of 
her birth. She was healthy looking on examination and 
weighed 19kg, 86% of the expected. Apart from a hard, 
non tender mass with irregular surface in the right 
hypochondrium extending toward the xphisternum, that 
measures 6cm below the right costal margin, otherwise 
abdomen was not distended. Other systemic 
examinations were normal. Her heamatological 
parameters and viral screening were normal. The 
serum level of AFP was ≥ 10,000ng/ml. Abdominal 
ultrasound showed a huge hyperechoic mass involving 
primarily the right lobe of liver measuring 15.7cm x 11.5 
x 13.6 cm. Her chest X-ray was normal. A fine needle 
aspiration of the mass was suspicious of malignancy. 
The peritoneum was opened through a right subcostal 
hockey stick incision with a 3cm vertical extension 
toward the xphisternum. Intra operatively, a huge 
encapsulated grayish looking mass (stage I) COG 
Figure 2 involving the right lobe of the liver was found. 
An extended right hepatectomy was performed using 
diathermy coagulation combined with Pringles 
maneuver to remove the mass.500mls of blood was 
transfused intraoperatively. Grossly it weighed 560g. 
Histology of the mass showed liver tissues displaying 
fairly circumscribed malignant epithelial neoplasm, 
separated by fibrous bands forming nodular 
configurations with some focal areas showing 
differentiated chondroid and osteoid depositions, which 
were consistent with hepatoblastoma with teratoid 
features. Five courses 5 of three weekly combined 
adjuvant cisplatin 60mg/m2 and doxorubicin 30mg/m2 
(PLADO) was administered. On completion of 
chemotherapy, the alpha-feto protein level dropped by 
more than 90% of its initial value. Her follow up had 
remained uneventful with regular (Figure 3) abdominal 
ultrasound scan and alpha fetoprotein. 
DISCUSSION  
The aetiology of hepatoblastoma is still obscure, but 
has been associated with young maternal age < 
20years, body mass index (BMI > 25), very low birth 
weight <1000g, perinatal oxygen therapy, treatment for 
infertility, and maternal substance abuse [9]. Certain 
genetic conditions such as: Beckwith-wiedemann 
syndrome, familial adematous polyposis, Gardner’s 
syndrome, hemihypertrophy though not common but 
have been associated with hepatoblastoma [10, 11]. 
Young maternal age is the likely risk factor in our 
reports because both mothers were younger than 20 
years. 
The presentation in hepatoblastoma is almost 
similar to one of the most commonly diagnosed 
abdominal tumour in childhood in our environment. It 
presents as a painless abdominal mass, in an 
otherwise healthy looking child [12, 13]. Malaise, poor 
nutritional state from cancer cachexia will be obvious 
with advanced disease state. Jaundice is unlikely 
except when there is hilar obstruction by the tumour. At 
time there may be sudden intra tumoral or intra 
peritoneal haemorrhage leading to emergency 
presentation as seen in one of the patient that 
presented in acute respiratory distress with severe 
anaemia due to intra tumoral hemorrhage. 
 
Figure 2a: Intra operative appearance of the right liver mass in the 7 year old girl. 
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Occasionally there will be thrombocytosis because of 
excessive production of thrombopoietin by the tumour 
that can be picked on routine blood film [14]. 
 
Figure 3: The 7 year old girl at her recent follow up 15 
months after chemotherapy. 
Ultrasound scan is the most common imaging tool 
for diagnosis of liver tomours, [15] however, when 
available computarised tomography scan (CT) or 
magnetic resonance imaging (MRI) gives superior 
definition of segmental involvement of the liver by the 
tumour in addition to tumour stage. Tumour 
echogenicty, dimension, and extension to the inferior 
vena cava and portal tract structures was determine 
with only abdominal ultra sound in this report. 
The serum level of AFP was excessively elevated in 
both patients, even though other liver tumours such as 
hepatocelluar carcinoma, vascular tumours of the liver, 
harmatomas, adenomas and germ cell tumours, also 
produce AFP but not to such a very high level as with 
hepatoblastoma [16]. AFP is a protein predominantly 
produced by fetal yolk sac, liver hepatocytes and the 
gastrointestinal tract. Normal serum level of < 30ng/ml 
is often attained by 6 months to 1 year of life. Children 
with hepatoblastoma will have AFP level higher than 
normal for their age [17] Majority of children with 
hepatoblastoma will have an initial AFP level of 
between 100,000 and 1,000,000ng/ml especially the 
favorable histologic (pure fetal) subtype of 
hepatoblastoma [18]. Low levels of AFP < 100ng/ml is 
often encountered in small cell undifferentiated 
subtypes of hepatoblastoma, because of the decreased 
number of hepatocytes that secrete this protein in this 
subtype of hepatoblastoma which may suggest poor 
prognosis [19]. 
During the surgery, dissection of the liver tissue was 
performed with monopolar diathermy coagulation 
simultaneously with Pringle manoeuvre released after 
every 30minutes minimizing bleeding. The cut surface 
area was sutured over a cellulose polymer (surgicel) 
with an absorbable suture. The liver was not mobilized 
in the first patient because the tumour was 
pedunculated. Complete mobilization was done in the 
 
Figure 2a: The appearance of mass after it was excised in a 7 year old girl. 
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second patient because of the size of the tumour which 
eased the resection. 
Based on the histologic subtype and stage of the 
first patient, adjuvant cisplatin monotherapy was 
administered as according to reports, [20, 21] who 
confirm the efficacy of cisplatin monotherapy in stage I 
hepatoblastomas with favourable histology (fetal 
subtype), that completely resected. The histologic 
subtype of the second patient was unfavorable 
because of the presence of the teratiod features even 
though it was a completely resected stage I 
hepatoblastoma. Therefore received combined 
adjuvant chemotherapy PLADO. 
The PRETEXT (pre treatment extent of disease 
based on radiologic location of the tumour) by the 
International Society of Paediatric Oncology (SIOP) 
and the clinical staging system by the COG are the 
most frequently used staging systems for 
hepatoblastoma [22]. The COG staging system is 
convenient for us because of our limited experience 
with this tumour and due to limlted availability of 
superior imaging studies such as CT scan and MRI in 
our own environment to stage the tumour before 
surgery. 
Finally, the histologic characteristics of 
hepatoblastoma are important in streamlining 
overzealous exposure to the adverse effects of 
chemotherapy. A prognostically favorable histologic 
subtype, stage I, with serum AFP level > 10,000ng/ml 
like in the first case can receive a single 
chemotherapeutic agent as have been proven from 
multicentre clinical trial study groups [23]. 
Currently the two patients are doing well; the first 
patient is 18 months post chemotherapy, while the 
second patient is 15 months. Their follow is every 6 
months with AFP assay. 
In conclusion, hepatoblastoma is not a common 
tumour in our environment, however with proper 
planning and from experiences of previous studies its 
outcome is in no way different from the previous 
reports. 
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